Anthem (NASDAQ:ANTX) & Aerovate Therapeutics (NASDAQ:AVTE) Head-To-Head Contrast

Anthem (NASDAQ:ANTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Anthem and Aerovate Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1	0	1	0	2.00
Aerovate Therapeutics	0	0	0	0	0.00

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 101.52%. Given Anthem’s stronger consensus rating and higher possible upside, research analysts plainly believe Anthem is more favorable than Aerovate Therapeutics.

Valuation and Earnings

This table compares Anthem and Aerovate Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17 million	($1.10)	-4.06
Aerovate Therapeutics	N/A	N/A	-$75.52 million	($1.70)	-8.98

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

90.5% of Anthem shares are held by institutional investors. 24.5% of Anthem shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Anthem and Aerovate Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Volatility & Risk

Anthem has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Summary

Anthem beats Aerovate Therapeutics on 9 of the 11 factors compared between the two stocks.

About Anthem

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.